These 30 employees of Ruikang Electronics have not been in the office area on the 14th floor for long.

But after just about a week of running-in, these newly hired engineers started R&D work.

The entire 14th floor of Binhai Building has been converted into two R&D departments, half of which is the microprocessor chip R&D department, and the other half is the camera sensor R&D department. The two departments are working together to develop two major electronic components of wearable vision devices.

Because this device itself needs to be implanted into the human eye socket, how to ensure correct docking with the optic nerve, the response to the rejection reaction of foreign objects implanted into the human body, and the genetic code of the retinal provided by Chen Changan, the problem of converting light signals into biological signals requires the participation of biological researchers.

The Nandou R&D team on Wang Jia is responsible for studying biological-oriented topics in human-computer interaction, neural docking, biosensing, and anti-rejection projects.

With Chen Chang'an's coordination in the middle and given a large amount of technical data, the R&D work on both sides was smoothly on the right track.

Chen Changan also started his busy work again. On the one hand, he needed to control the development of electronic equipment on Ruikang Electronics and participate in research and development. On the other hand, the retinal genetic code decryption work on the research center also needed his help!

Because he is a person who knows the complete genetic code of the retinal, without his participation, the progress would be very slow to rely on Fu Yi and more than a dozen researchers alone.

Chen Changan had to take care of both sides and ran back and forth between the company and the R&D center every day.

This made him even more urgent to open the new headquarters. The new headquarters, production center and scientific research center are connected together. It takes less than ten minutes to walk between the three places. It does not take about an hour to drive every day when you spend traveling!

While Chen Changan was busy participating in the research and development work between the two places, he was also asking Guan Kou to urge the construction company to complete the final work of the new headquarters as soon as possible.

Time passes slowly in this busy time.

....................................................

Just when Chen Changan was obsessed with the research and development of wearable vision devices, clinical trials of gene-edited drugs were also underway in Denmark, far away in Europe.

Denmark Oborg University Hospital.

Medical professors from Oborough University are carrying out related clinical work with the help of several researchers sent by Yun Heng from the headquarters.

"Hey, lee, your Ruikang Medical products are incredible!"

After seeing the clinical trial records of the first subject with his own eyes, Mr. Nicole, a professor of clinical medicine at the University of O'Borg, immediately came to Li Wei, the head of the research group dispatched by the Nandou Research Center, and pulled him excitedly, wanting to discuss with him how this gene-editing drug has such a magical therapeutic effect.

However, Li Wei refused him coldly: "Professor Nicole, I can't talk to you too much. You know, this involves the technical secrets of our company. This gene editing drug will be the next stage of Ruikang Medical's flagship product. All information about gene editing drugs is kept confidential."

"Oh   no!lee, don't be so ruthless. I just want to have a simple academic exchange with you. This will not involve the core secret of your gene editing drugs!" Professor Nicole still unwillingly tried to chat with Li Wei.

But Li Wei still said unmovedly: "I'm sorry, Professor Nicole, all I can tell you is one sentence. This is a drug developed based on gene editing technology. You have already seen the therapeutic effect. No matter how much information you have, there is nothing to tell."

"Okay OK, then let's talk about the effect of treatment. I heard from your team members that you have conducted phase 3 clinical trials of this drug in China. There are nearly a thousand voluntary subjects who have received treatment, and the treatment effect is very good. You can talk to me in detail. How many cancers are effective for this drug? Are the treatment effects of different cancers vary greatly?"

"Is it possible that this drug can really cure cancer completely?"

Professor Nicole speaks very fast, and his English has a little bit of an Eastern European accent. If Li Wei had not studied in Europe before, he had a Danish senior brother when he was studying for his doctorate, otherwise he might not have heard clearly what Professor Nicole was saying.

The questions he asked did not involve any technically confidential information, but were all questions about the effectiveness of drug use, so Li Wei didn't mind chatting with him.

He reached out to signal Professor Nicole to go with him, and explained, "Then let's talk while walking. There is a subject to surgery in the afternoon. I want to go to the surgical area to see the situation."

"No problem!" Professor Nicole followed Li Wei happily and talked to him about the clinical trials of gene editing drugs in China.

Li Wei had no intention of hiding it, and seriously told Nicole about the clinical situation in China.

At present, nearly a thousand Chinese subjects have basically achieved a certain degree of cancer cell inhibition effect.

However, depending on the differences between different cancers and the complexity of the disease, the effects vary. Some cancers with low malignancy are basically removed after early patients undergoing a combination of drug treatment and surgical resection.

Moreover, the body also produces cancer cell immune weapons. Once they relapse again, the immune weapons in the body will fight against the cancer cells themselves, inhibit the growth of cancer cells, and can at least fight for patients with 10-20 years of survival.

Some cancers like leukemia do not produce tumors but can infect normal cell tissues. After receiving drug treatment, they can also eliminate 70%-80% of the cancer cells in the patient's body at one time, greatly reducing the severity of the patient's condition and inhibiting the growth and reproduction rate of the remaining cancer cells for a long time, which is also quite gratifying.

Even some middle and late stage cancers that have metastasized and spread throughout the body can eliminate most cancer cells at one time after receiving timely drug treatment!

However, because it has spread in multiple points in the body, the recurrence and proliferation of these cancer cells is several times faster than that in the middle and middle stages. Even if the dosage is increased and multiple injections of gene editing drugs inhibit the development of cancer cells can only delay the survival of 5-10 years.

However, compared with the average survival period of advanced cancer in several months, it has increased several times.

Professor Nicole heard that even the malignant advanced cancer, which had a survival period of only three months to six months, could extend the survival period of 5-10 years, and almost fell off his chin.

"OMG! Li, is this gene editing drug in your company so effective?"

"I have a good friend who unfortunately suffered from lung cancer. He had a tumor resection, but it relapsed not long after. Now he is in very bad health. Is this gene editing drug effective for him?"

Li Wei raised his eyebrows and looked at Professor Nicole with some anticipation in his expression. He did not disappoint his expectations. He smiled and nodded and said, "Of course it works. If your friend needs it, you can sign up for the clinical trial. The subjects have not been recruited yet."
Chapter completed!